Coenzyme Q10 in Cardiovascular Medicine: Mechanisms, Clinical Evidence, and Future Integration in Heart Failure and Statin Myopathy

Coenzyme Q10 (CoQ10), or ubiquinone, is a lipid-soluble antioxidant essential for mitochondrial adenosine triphosphate production and cellular energy metabolism. Its therapeutic potential has been investigated in conditions marked by mitochondrial dysfunction, particularly chronic heart failure and statin-associated muscle symptoms. Robust evidence, including data from the Q-SYMBIO trial, demonstrates that CoQ10 supplementation can improve functional capacity, ejection fraction, and reduce major cardiovascular events in heart failure with reduced ejection fraction. However, studies on its efficacy for statin myopathy have yielded inconsistent results, with some reporting symptom relief and others showing no significant benefit. CoQ10 is generally safe, well-tolerated, and affordable, and emerging research supports its classification as a conditionally essential nutrient in heart failure. While routine supplementation for all statin users is not currently recommended, targeted use in advanced heart failure with reduced ejection fraction or in patients with high mitochondrial demand may be justified. As further evidence and cost-effectiveness data become available, formal guideline recommendations for CoQ10 may follow.